Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma.
Pallavi Sachdev
Employment or Leadership Position - Eisai
Omid Hamid
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Kevin Kim
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; Oncoscience; Roche
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; Oncoscience; Roche
Steven O'Day
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Corina Andresen
Employment or Leadership Position - Eisai
Yasuhiro Funahashi
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
Tadashi Kadowaki
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
James P. O'Brien
Employment or Leadership Position - Eisai
Keith Flaherty
Consultant or Advisory Role - Eisai
Research Funding - Eisai